NEOS Investment Management LLC Buys 6,304 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• NEOS Investment Management increased its Thermo Fisher stake by 11.5% in the second quarter, adding 6,304 shares and bringing its holdings to 61,295 shares valued at approximately $30.7 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion; revenue grew 10.5% year over year. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $619.41. The company also declared a quarterly dividend of $0.47 per share, while recent insider activity was net selling.

NEOS Investment Management LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.5% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 61,295 shares of the medical research company's stock after acquiring an additional 6,304 shares during the quarter. NEOS Investment Management LLC's holdings in Thermo Fisher Scientific were worth $30,731,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of TMO. Tsfg LLC increased its holdings in Thermo Fisher Scientific by 20.4% in the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company's stock valued at $56,000 after buying an additional 19 shares during the period. Elyxium Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock worth $613,000 after acquiring an additional 20 shares in the last quarter. Renasant Bank increased its stake in Thermo Fisher Scientific by 1.0% in the second quarter. Renasant Bank now owns 1,934 shares of the medical research company's stock valued at $970,000 after acquiring an additional 20 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Finally, Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its stake in Thermo Fisher Scientific by 0.7% during the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock worth $1,436,000 after purchasing an additional 20 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $612.75 on Friday. The stock has a market cap of $226.56 billion, a price-to-earnings ratio of 32.96, a P/E/G ratio of 2.59 and a beta of 0.85. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $647.00. The company's fifty day moving average is $570.91 and its 200 day moving average is $515.10. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. The business's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc Casper sold 275 shares of the business's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 73,768 shares of company stock worth $44,122,820. Corporate insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TMO shares. Barclays boosted their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a "market perform" rating and a $520.00 target price on the stock. Evercore set a $570.00 target price on Thermo Fisher Scientific in a research note on Monday, July 6th. Jefferies Financial Group restated a "buy" rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, Royal Bank Of Canada lifted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.